Replies to post #163196 on Biotech Values

[oc631]

ABBV’s ABT-450-based regimen uses ritonavir at half the normal PK-boosting dose; if this regimen were using ritonavir at full strength, it would be much more of a detriment to commercial uptake.

Perhaps you are more qualified to answer McBio's question. Is there enough hard data on the efficacy of ABT-450 in combination with PegRiba? If so which drug (in your opinion) appears superior?